Ulcerative Colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with Fecal Calprotectin, Clinical Activity, C-reactive Protein, and Blood Leukocytes

被引:277
作者
Schoepfer, Alain M. [1 ,2 ]
Beglinger, Christoph [3 ]
Straumann, Alex [3 ]
Trummler, Michael [4 ]
Renzulli, Pietro [5 ]
Seibold, Frank [2 ]
机构
[1] McMaster Univ, Farncombe Family Inst Digest Hlth Res, Hamilton, ON L8N 3Z5, Canada
[2] Univ Hosp Bern, Inselspital, Dept Visceral Surg & Med, CH-3010 Bern, Switzerland
[3] Univ Basel Hosp, Dept Gastroenterol, CH-4031 Basel, Switzerland
[4] Bioanalyt Med Labs, Luzern, Switzerland
[5] Univ Bern, Inselspital, Dept Visceral Surg & Med, CH-3010 Bern, Switzerland
基金
瑞士国家科学基金会;
关键词
fecal calprotectin; ulcerative colitis; biomarkers; disease activity; Rachmilewitz Activity Index; INFLAMMATORY-BOWEL-DISEASE; INTESTINAL INFLAMMATION; 5-AMINOSALICYLIC ACID; SURROGATE MARKERS; COLORECTAL-CANCER; RELAPSE; RISK; CRP; PERFORMANCE; PARAMETERS;
D O I
10.1002/ibd.20986
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (UC) according the Rachmilewitz Score is so far unknown. The aim was to evaluate the correlation between endoscopic disease activity and fecal calprotectin. Clinical Activity Index, C-reactive protein (CRP), and blood leukocytes. Methods: UC patients undergoing colonoscopy were prospectively enrolled and scored independently according the endoscopic and clinical part of the Rachmilewitz Index. Patients and controls provided fecal and blood samples for measuring calprotectin, CRP, and leukocytes. Results: Values in UC patients (n = 134) compared to controls (n = 48): calprotectin: 396 +/- 351 versus 18.1 +/- 5 mu g/g, CRP 16 +/- 13 versus 3 +/- 2 mg/L, blood leukocytes 9.9 +/- 3.5 versus 5.4 +/- 1.9 g/L (all P < 0.001). Endoscopic disease activity correlated closest with calprolectin (Spearman's rank correlation coefficient r = 0.834), followed by Clinical Activity Index (r = 0.672), CRP (r = 0.503), and leukocytes (r = 0.461). Calprotectin levels were significantly lower in UC patients with inactive disease (endoscopic score 0-3, calprotectin 42 +/- 38 mu g/g), compared to patients with mild (score 4-6, calprotectin 210 +/- 121 mu g/g, P < 0.001), moderate (score 7-9, calprotectin 392 +/- 246 mu g/g, P = 0.002), and severe disease (score 10-12, calprotectin 730 +/- 291 mu g/g, P < 0.001). The overall accuracy for the detection of endoscopically active disease (score >4) was 89% for calprotectin, 73% for Clinical Activity Index, 62% for elevated CRP, and 60% for leukocytosis. Conclusions: Fecal calprotectin correlated closest with endoscopic disease activity, followed by Clinical Activity Index, CRP, and blood leukocytes. Furthermore, fecal calprotectin was the only marker that reliably discriminated inactive from mild, moderate, and highly active disease, which emphasizes its usefulness for activity monitoring.
引用
收藏
页码:1851 / 1858
页数:8
相关论文
共 36 条
[1]   Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease [J].
Arnott, IDR ;
Watts, D ;
Ghosh, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (05) :857-867
[2]   Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis [J].
Bitton, A ;
Peppercorn, MA ;
Antonioli, DA ;
Niles, JL ;
Shah, S ;
Bousvaros, A ;
Ransil, B ;
Wild, G ;
Cohen, A ;
Edwardes, MDD ;
Stevens, AC .
GASTROENTEROLOGY, 2001, 120 (01) :13-20
[3]   Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease [J].
Canani, R. Berni ;
Terrin, G. ;
Rapacciuolo, L. ;
Miele, E. ;
Siani, M. C. ;
Puzone, C. ;
Cosenza, L. ;
Staiano, A. ;
Troncone, R. .
DIGESTIVE AND LIVER DISEASE, 2008, 40 (07) :547-553
[4]   Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels [J].
Carlson, CS ;
Aldred, SF ;
Lee, PK ;
Tracy, RP ;
Schwartz, SM ;
Rieder, M ;
Liu, KA ;
Williams, OD ;
Iribarren, C ;
Lewis, EC ;
Fornage, M ;
Boerwinkle, E ;
Gross, M ;
Jaquish, C ;
Nickerson, DA ;
Myers, RM ;
Siscovick, DS ;
Reiner, AP .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 77 (01) :64-77
[5]   Acceptance of colonoscopy requires more than test tolerance [J].
Condon, Amanda ;
Graff, Lesley ;
Elliot, Lawrence ;
Ilnyckyj, Alexandra .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 22 (01) :41-47
[6]   Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368
[7]   Can calprotectin predict relapse risk in inflammatory bowel disease? [J].
D'Inca, Renata ;
Dal Pont, Elisabetta ;
Di Leo, Vincenza ;
Benazzato, Luca ;
Martinato, Matteo ;
Lamboglia, Francesca ;
Oliva, Lydia ;
Sturniolo, Giacomo Carlo .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08) :2007-2014
[8]   The role of endoscopic assessment in ulcerative colitis in the era of infliximab [J].
Daperno, M. ;
Sostegni, R. ;
Pera, A. ;
Rognone, D. ;
Rigazio, C. ;
Ercole, E. ;
Crocella, L. ;
Lavagna, A. ;
Rocca, R. .
DIGESTIVE AND LIVER DISEASE, 2008, 40 :S220-S224
[9]   Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort [J].
Froslie, Kathrine Frey ;
Jahnsen, Jorgen ;
Moum, Bjorn A. ;
Vatn, Morten H. .
GASTROENTEROLOGY, 2007, 133 (02) :412-422
[10]  
Johne B, 1997, J CLIN PATHOL-MOL PA, V50, P113